Neoantigen-Based Personalized Cancer Vaccine: LNP-Mediated Delivery Of Multi-Epitope mRNA Extends Survival In Aggressive Melanoma Cancer Model

By Jay Paquette, Mehar Gayatri Namala, Leanna Yee, Sams M. A. Sadat, Ruchi Sharma, Darius Menezes, Pierrot Harvie, Nikita Jain, Zhengyu Chen, Malathi Anantha, Tony Wu, Vicente Lacap, Richard Jiang, Vinay Mayya, Sijo Chemmannur, Avisek Deyati, and Anitha Thomas

Personalized cancer vaccines are reshaping immunotherapy by training the immune system to recognize neoantigens unique to each patient’s tumor. As clinical progress pushes multiple solid tumor programs into Phase III, attention is shifting from promise to performance. Lipid nanoparticle-based mRNA delivery offers a flexible way to package multiple neoantigen targets, but success depends on more than payload design alone. Key challenges include improving tissue targeting, enhancing endosomal escape, and supporting repeat dosing without compromising therapeutic impact. Understanding how these factors work together is essential for translating personalized cancer vaccines into reliable, scalable treatment strategies.

Explore the scientific and formulation considerations driving the next generation of PCV development.